Alk-Abello AS (CHIX:ALKBC) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ALKBC Alk-Abello AS CHIX:ALKBC
91 GF Score
Price kr256.30
GF Value kr220.00
Valuation Modestly Overvalued
View Full Analysis

What is Alk-Abello AS Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

CHIX:ALKBC
91GF Score
Alk-Abello AS CHIX:ALKBC
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?

Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued. The current stock price of kr256.30 is trading 16.5% above its estimated GF Value™ of kr220.00. GuruFocus considers Alk-Abello AS to be Modestly Overvalued.

Key valuation signals for CHIX:ALKBC:

  • Total Noninterest Expense:
  • GF Value™: kr220.00 vs. price of kr256.30 (16.5% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alk-Abello AS Business Description

Address Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
91GF Score

Get the complete analysis for CHIX:ALKBC

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr256.30
Price
kr220.00
GF Value